Scopus: Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies
dc.contributor.author | Kocaturk I. | |
dc.contributor.author | Gulten S. | |
dc.contributor.author | Ece B. | |
dc.contributor.author | Kukul Guven F.M. | |
dc.date.accessioned | 2024-04-15T07:19:06Z | |
dc.date.available | 2024-04-15T07:19:06Z | |
dc.date.issued | 2024-03-01 | |
dc.identifier | 10.3390/diagnostics14060635 | |
dc.identifier.doi | 10.3390/diagnostics14060635 | |
dc.identifier.scopus | 2-s2.0-85188906507 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12597/33084 | |
dc.relation.ispartof | Diagnostics | |
dc.relation.ispartofseries | Diagnostics | |
dc.rights | true | |
dc.subject | C-reactive protein | fibrinogen | inflammation | lipoxin A4 | migraine | prostaglandin E2 | |
dc.title | Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies | |
dc.type | Journal | |
dspace.entity.type | Scopus | |
oaire.citation.issue | 6 | |
oaire.citation.volume | 14 | |
person.affiliation.name | Kastamonu University | |
person.affiliation.name | Kastamonu University | |
person.affiliation.name | Kastamonu University | |
person.affiliation.name | Kastamonu University | |
person.identifier.orcid | 0000-0002-3415-6906 | |
person.identifier.orcid | 0000-0001-5134-1620 | |
person.identifier.orcid | 0000-0001-6288-8410 | |
person.identifier.orcid | 0000-0003-3755-6021 | |
person.identifier.scopus-author-id | 36084791600 | |
person.identifier.scopus-author-id | 55331044900 | |
person.identifier.scopus-author-id | 57190287798 | |
person.identifier.scopus-author-id | 25622351200 |